Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 107

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part II, Item 1A
Chunk 107
---
, capital appreciation, if any, will be the sole source of gain for our stockholders. 

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.  

56

Item 5. Other Information

(c) Director and Officer Trading Arrangements 

A significant portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other of our securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.

Transactions in our securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information. 

None of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this report.

57

Item 6.    ExhibitsIncorporated by ReferenceExhibitNumberDescription of ExhibitFormFile NumberDate of FilingExhibitNumberFiledHerewith3.1Restated Certificate of Incorporation8-K001-36014July 30, 20133.13.2Third Amended and Restated By-Laws8-K001-36014March 3, 20233.110.1#2023 Stock Incentive Plan, as amendedS-8333-288151June 18, 202599.110.2Sublease Agreement, dated June 5, 2025, between the Registrant and GNS Healthcare, Inc. d/b/a Aitia (64 Sidney Street)X31.1Certification of principal executive officer pursuant to